Q.1
Revenue growth of Covidh Technologies Ltd?
Covidh Technologies Ltd revenue growth is 0% for FY-2025 , which is above its 5 year CAGR of -33.8% , indicating faster growth.
Q.2
Gross Profit margin of Covidh Technologies Ltd?
Covidh Technologies Ltd Gross profit margin which is the profit after deduction of direct costs, is 52.4% for FY-2025 , which is above its 5 year median of 0% , indicating increasing margins.
Q.3
Operating Profit Margin of Covidh Technologies Ltd?
Covidh Technologies Ltd Operating Profit Margin which is the profit after deduction of all operating costs, is 52.41% for FY-2025 , which is above its 5 year median of 0% indicating increasing margins.
Q.4
Net Profit Margin of Covidh Technologies Ltd?
Covidh Technologies Ltd Net Profit Margin is 52.41% for FY-2025 , is above with its 5 year median of -%, indicating increasing margins.
|
Current Level |
Historic Median |
|
Gross Profit Margin |
52.4 |
- |
|
Operating Profit Margin |
52.41 |
- |
|
Net Profit Margin |
52.41 |
- |
Q.5
Return on Asset of Covidh Technologies Ltd?
Covidh Technologies Ltd Return on Asset is 17.28(x), which is above its 5 year historical median of -4.69(x), indicating improved asset utilization efficiency.
Q.6
Return on Equity (ROE) of Covidh Technologies Ltd?
Covidh Technologies Ltd Return on equity is 0% for FY-2025 , which is in line with its historical median of 0%, indicating the business is making similar use of its shareholders capital.
Q.7
Return on capital employed (ROCE) of Covidh Technologies Ltd?
Covidh Technologies Ltd Return on capital employed is 18.82% for FY-2025 , which is above its estimated weighted average cost of capital(WACC) 14%, indicating value creation.
Q.8
Cash conversion cycle of Covidh Technologies Ltd?
Covidh Technologies Ltd Cash conversion cycle is -160 , below its historical median of 0 , indicating improved working capital management. However, you need to compare this with its peers in the industry.
|
Current Level |
Historic Median |
|
Asset Turnover |
0.33 |
- |
|
ROE |
- |
- |
|
ROCE |
18.82 |
-4.64 |
|
Cash Conversion Cycle |
-160 |
- |
Q.9
Debt to Equity ratio of Covidh Technologies Ltd?
Covidh Technologies Ltd Debt-to-Equity ratio is -16.38 , which is lower with the industry average of 0.01 , indicating lower debt levels in the industry.
Q.10
Debt to cash flow from operations of Covidh Technologies Ltd?
Covidh Technologies Ltd Debt to cash flow from operations is -1.15 , which is at a unhealthy level, indicating the business is not able to service its debt comfortably.
Q.11
Revenue growth of iSERA Lifesciences Ltd?
iSERA Lifesciences Ltd revenue growth is 0% for FY-2025 , which is above its 5 year CAGR of -33.8% , indicating faster growth.
Q.12
Gross Profit margin of iSERA Lifesciences Ltd?
iSERA Lifesciences Ltd Gross profit margin which is the profit after deduction of direct costs, is 52.4% for FY-2025 , which is above its 5 year median of 0% , indicating increasing margins.
Q.13
Operating Profit Margin of iSERA Lifesciences Ltd?
iSERA Lifesciences Ltd Operating Profit Margin which is the profit after deduction of all operating costs, is 52.41% for FY-2025 , which is above its 5 year median of 0% indicating increasing margins.
Q.14
Net Profit Margin of iSERA Lifesciences Ltd?
iSERA Lifesciences Ltd Net Profit Margin is 52.41% for FY-2025 , is above with its 5 year median of -%, indicating increasing margins.
|
Current Level |
Historic Median |
|
Gross Profit Margin |
52.4 |
- |
|
Operating Profit Margin |
52.41 |
- |
|
Net Profit Margin |
52.41 |
- |
Q.15
Return on Asset of iSERA Lifesciences Ltd?
iSERA Lifesciences Ltd Return on Asset is 17.28%, which is above its 5 year historical median of -4.69%, indicating improved asset utilization efficiency.
Q.16
Return on Equity (ROE) of iSERA Lifesciences Ltd?
iSERA Lifesciences Ltd Return on equity is 0% for FY-2025 , which is in line with its historical median of 0%, indicating the business is making similar use of its shareholders capital.
Q.17
Return on capital employed (ROCE) of iSERA Lifesciences Ltd?
iSERA Lifesciences Ltd Return on capital employed is 18.82% for FY-2025 , which is above its estimated weighted average cost of capital(WACC) 14%, indicating value creation.
Q.18
Cash conversion cycle of iSERA Lifesciences Ltd?
iSERA Lifesciences Ltd Cash conversion cycle is -160 days, below its historical median of 0 days, indicating improved working capital management. However, you need to compare this with its peers in the industry.
|
Current Level |
Historic Median |
|
Asset Turnover |
0.33 |
- |
|
ROE |
- |
- |
|
ROCE |
18.82 |
-4.64 |
|
Cash Conversion Cycle |
-160 days |
- |
Q.19
Debt to Equity ratio of iSERA Lifesciences Ltd?
iSERA Lifesciences Ltd Debt-to-Equity ratio is -16.38 , which is lower with the industry average of 0.01 , indicating lower debt levels in the industry.
Q.20
Debt to cash flow from operations of iSERA Lifesciences Ltd?
iSERA Lifesciences Ltd Debt to cash flow from operations is -1.15 , which is at a unhealthy level, indicating the business is not able to service its debt comfortably.
